Close Menu

Breaking News

The findings underscore the value of carrying out large-scale human genetic analyses as part of drug target identification and validation efforts. 

 

 

The company said it will use the funds in part to continue development of its artificial intelligence-based proteome-wide drug discovery platform.

Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.

Gencurix' RT-PCR-based test detects SARS-CoV-2's Orf1-ab and RdRP genes, while Laihe's assay is designed to detect antibodies against the virus.

Sex differences in muscle gene expression were further reduced with long-term endurance exercise, an international research team found.

Using Genotype-Tissue Expression project samples, researchers put together gene regulatory networks for 29 tissue types, uncovering extensive sex-related regulatory differences.

Molecular Assemblies will combine its chemistries with Codexis' enzyme improvement platform in order to create a process for the enzymatic synthesis of DNA.

The latest group includes several firm developing genomics tools or diagnostics, but COVID-19 is preventing them from accessing their lab space for the time being.

Facing questions over data security in the US and Ireland, the company has changed its name as it looks to shed its China operations.

The assay will identify patients with mutations in HER2 who may be eligible for treatment with a HER2-directed antibody-drug-conjugate developed by Daiichi.

Along with significantly mutated genes across cutaneous melanoma cases, researchers saw loss-of-function mutations in the X chromosome gene DDX3X in tumors from male patients.

RNA-seq of ascites from ovarian cancer patients uncovered shared inflammatory programs and suggested a JAK/STAT pathway inhibitor has antitumor activity.

Last week, GenomeWeb's readers were most interested in a judge granting Illumina a preliminary injunction to prevent BGI from distributing its sequencing platforms in the US.

The companies are developing a lung cancer liquid biopsy assay that will run on desktop sequencers, with plans to apply for regulatory clearance in China.

BioSkryb will now have an exclusive global license for clinical applications of primary template directed amplification technology.

The company sells a number of next-generation sequencing-based tissue and liquid biopsy tests for cancer therapy selection to the Chinese market.

By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.

The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.

Study subjects of both sexes who had low germline mutation rates lived nearly five years longer than individuals with high mutation rates.

The tests are designed to detect regions in the SARS-CoV-2 genome in respiratory samples or antibodies against the virus in human serum, plasma, or blood.

Researchers identified secondary or incidental findings in just over 3 percent of the nearly 22,000 EMERGE III participants, who were profiled with a 109-gene panel.

News items for the week of June 15, 2020. 

Because of coronavirus-related shutdowns of customer labs, the San Diego-based firm saw decreased revenues in all geographic regions, especially outside the US.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.